| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 22,534 | 24,006 | ||
| Marketable securities | 210,023 | 50,974 | ||
| Accounts receivable from collaboration with a related party | 912 | - | ||
| Prepaid expenses and other current assets | 3,343 | 2,487 | ||
| Total current assets | 236,812 | 77,467 | ||
| Property and equipment, net | 229 | 219 | ||
| Operating lease right-of-use (rou) assets | 2,644 | 2,782 | ||
| Other assets | 312 | 312 | ||
| Total assets | 239,997 | 80,780 | ||
| Accounts payable | 1,683 | 743 | ||
| Accrued research and development expenses | 3,058 | 1,691 | ||
| Other accrued expenses | 5,728 | 3,407 | ||
| Deferred revenue from a related party - short-term | 42,363 | 40,917 | ||
| Operating lease liabilities - short-term | 548 | 533 | ||
| Total current liabilities | 53,380 | 47,291 | ||
| Deferred revenue from a related party - long-term | 1,715 | 13,038 | ||
| Operating lease liabilities - long-term | 2,207 | 2,351 | ||
| Total liabilities | 57,302 | 62,680 | ||
| Common stock, 0.001 par value 150,000,000 shares authorized as of september 30, 2025 and december 31, 2024 15,816,987 and 7,457,240 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 16 | 8 | ||
| Additional paid-in capital | 1,036,906 | 863,312 | ||
| Accumulated other comprehensive loss | -90 | -279 | ||
| Accumulated deficit | -854,137 | -844,941 | ||
| Total stockholders' equity | 182,695 | 18,100 | ||
| Total liabilities and stockholders' equity | 239,997 | 80,780 | ||
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)